{
    "abstract": "Background: Over the last decades, pertussis showed periodic increases in its incidence among adults, despite being a vaccine-preventable disease. Methods: This phase III, multicenter, extension study (NCT00489970) was conducted in adults from the United States, followed at Year (Y) 5 and Y9 post-vaccination with a dose of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine containing either 3 (Tdap-B group) or 5 pertussis components (Tdap-A group). Willing participants in Tdap groups and newly-recruited participants (Control group) received one Tdap-B dose at Y9. Antibody persistence (at Y5 and Y9) and safety of Tdap-B at Y9 were assessed. Non-inferiority of immune response elicited by 2 Tdap doses was evaluated at Y9: (i) versus one Tdap-B dose for diphtheria and tetanus in terms of seroprotection rates; (ii) for all antigens in terms of booster response rates (Tdap-B and Tdap-A groups versus Control group); and (iii) for pertussis antigens in terms of geometric mean concentrations (GMCs) versus a 3-dose series of a combined diphtheria-tetanus-acellular pertussis vaccine (DTPa) administered during infancy. Results: 1257 participants were enrolled at Y5 and 809 participants were vaccinated at Y9. Seroprotection rates in both Tdap groups were \u226598.4% and \u226598.0% (Y5) and \u226598.3% and \u226598.1% (Y9) for diphtheria and tetanus, respectively. For pertussis antigens, antibody concentrations above assay cut-offs were observed for \u226576.6% (Y5) and \u226584.9% (Y9) of participants in Tdap groups. At Y9, one month post-Tdap vaccination, comparable seroprotection/seropositivity rates and antibody GMCs were observed among groups. Non-inferiority of immune responses in both Tdap groups was demonstrated when compared to the Control group for diphtheria and tetanus and to a 3-dose DTPa series for pertussis antigens. Non-inferiority criteria in terms of booster response were not met for all antigens. No safety concerns were raised. Conclusion: A second dose of Tdap-B administered in adults, 9 years after initial Tdap vaccination, is immunogenic and well-tolerated.",
    "author_highlights": [
        {
            "endOffset": 17892,
            "sentence": "In vaccinated adults, pertussis antibody levels wane over time, but a Tdap dose boosts immunity.",
            "startOffset": 17796
        },
        {
            "endOffset": 18004,
            "sentence": "Diphtheria and tetanus seroprotection rates were high 5 (\u226598.0%) and 9 (\u226598.1%) years post-initial vaccination.",
            "startOffset": 17893
        },
        {
            "endOffset": 18098,
            "sentence": "Nine years post-vaccination, \u226584.9% of participants were seropositive for pertussis antigens.",
            "startOffset": 18005
        },
        {
            "endOffset": 18188,
            "sentence": "A dose of Tdap administered 9 years post-primary dose was immunogenic and well-tolerated.",
            "startOffset": 18099
        }
    ],
    "bib_entries": {
        "b0005": null,
        "b0010": null,
        "b0015": {
            "authors": [
                {
                    "first": "Tina",
                    "initial": "T.",
                    "last": "Tan"
                },
                {
                    "first": "Tine",
                    "initial": "T.",
                    "last": "Dalby"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Forsyth"
                },
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Ulrich",
                    "initial": "U.",
                    "last": "Heininger"
                },
                {
                    "first": "Daniela",
                    "initial": "D.",
                    "last": "Hozbor"
                },
                {
                    "first": "Stanley",
                    "initial": "S.",
                    "last": "Plotkin"
                },
                {
                    "first": "Rolando",
                    "initial": "R.",
                    "last": "Ulloa-Gutierrez"
                },
                {
                    "first": "Carl Heinz Wirsing",
                    "initial": "C.H.W.",
                    "last": "Von K\u00f6nig"
                }
            ],
            "doi": "10.1097/INF.0000000000000795",
            "firstpage": "e222",
            "issn": "08913668",
            "lastpage": "e232",
            "pmid": "26376316",
            "pub_year": 2015,
            "title": "Pertussis Across the Globe: Recent Epidemiologic Trends From 2000 to 2013",
            "volume": "34"
        },
        "b0020": {
            "authors": [
                {
                    "first": "Zhiyun",
                    "initial": "Z.",
                    "last": "Chen"
                },
                {
                    "first": "Qiushui",
                    "initial": "Q.",
                    "last": "He"
                }
            ],
            "doi": "10.1080/21645515.2016.1259780",
            "firstpage": "744",
            "issn": "21645515",
            "lastpage": "756",
            "pmid": "28045580",
            "pub_year": 2017,
            "title": "Immune persistence after pertussis vaccination",
            "volume": "13"
        },
        "b0025": {
            "authors": [
                {
                    "first": "Hyo Jin",
                    "initial": "H.J.",
                    "last": "Lee"
                },
                {
                    "first": "Jung Hyun",
                    "initial": "J.H.",
                    "last": "Choi"
                }
            ],
            "doi": "10.7774/cevr.2017.6.1.22",
            "firstpage": "22",
            "issn": "22873651",
            "lastpage": "30",
            "pub_year": 2017,
            "title": "Tetanus\u2013diphtheria\u2013acellular pertussis vaccination for adults: An update",
            "volume": "6"
        },
        "b0030": {
            "authors": [
                {
                    "first": "D.",
                    "initial": "D.",
                    "last": "Baratin"
                },
                {
                    "first": "C.",
                    "initial": "C.",
                    "last": "Del Signore"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Thierry"
                },
                {
                    "first": "E.",
                    "initial": "E.",
                    "last": "Caulin"
                },
                {
                    "first": "A. C.",
                    "initial": "A.C.",
                    "last": "Jacquard"
                },
                {
                    "first": "P.",
                    "initial": "P.",
                    "last": "Vanhems"
                }
            ],
            "doi": "10.1016/j.medmal.2014.07.001",
            "firstpage": "366",
            "issn": "0399077X",
            "lastpage": "373",
            "pmid": "25156676",
            "pub_year": 2014,
            "title": "Pertussis vaccination coverage among adults in the Lyon area",
            "volume": "44"
        },
        "b0035": {
            "authors": [
                {
                    "first": "Walter W.",
                    "initial": "W.W.",
                    "last": "Williams"
                },
                {
                    "first": "Peng Jun",
                    "initial": "P.J.",
                    "last": "Lu"
                },
                {
                    "first": "Alissa",
                    "initial": "A.",
                    "last": "O'Halloran"
                },
                {
                    "first": "David K.",
                    "initial": "D.K.",
                    "last": "Kim"
                },
                {
                    "first": "Lisa A.",
                    "initial": "L.A.",
                    "last": "Grohskopf"
                },
                {
                    "first": "Tamara",
                    "initial": "T.",
                    "last": "Pilishvili"
                },
                {
                    "first": "Tami H.",
                    "initial": "T.H.",
                    "last": "Skoff"
                },
                {
                    "first": "Noele P.",
                    "initial": "N.P.",
                    "last": "Nelson"
                },
                {
                    "first": "Rafael",
                    "initial": "R.",
                    "last": "Harpaz"
                },
                {
                    "first": "Lauri E.",
                    "initial": "L.E.",
                    "last": "Markowitz"
                },
                {
                    "first": "Alfonso",
                    "initial": "A.",
                    "last": "Rodriguez-Lainz"
                },
                {
                    "first": "Amy Parker",
                    "initial": "A.P.",
                    "last": "Fiebelkorn"
                }
            ],
            "doi": "10.15585/mmwr.ss6611a1",
            "firstpage": "1",
            "issn": "15460738",
            "lastpage": "28",
            "pmid": "28472027",
            "pub_year": 2017,
            "title": "Surveillance of vaccination coverage among adult populations-United States, 2015",
            "volume": "66"
        },
        "b0040": null,
        "b0045": {
            "authors": [
                {
                    "first": "Karen R.",
                    "initial": "K.R.",
                    "last": "Broder"
                },
                {
                    "first": "Margaret M.",
                    "initial": "M.M.",
                    "last": "Cortese"
                },
                {
                    "first": "John K.",
                    "initial": "J.K.",
                    "last": "Iskander"
                },
                {
                    "first": "Katrina",
                    "initial": "K.",
                    "last": "Kretsinger"
                },
                {
                    "first": "Barbara A.",
                    "initial": "B.A.",
                    "last": "Slade"
                },
                {
                    "first": "Kristin H.",
                    "initial": "K.H.",
                    "last": "Brown"
                },
                {
                    "first": "Christina M.",
                    "initial": "C.M.",
                    "last": "Mijalski"
                },
                {
                    "first": "Tejpratap",
                    "initial": "T.",
                    "last": "Tiwari"
                },
                {
                    "first": "Emily J.",
                    "initial": "E.J.",
                    "last": "Weston"
                },
                {
                    "first": "Amanda C.",
                    "initial": "A.C.",
                    "last": "Cohn"
                },
                {
                    "first": "Pamela U.",
                    "initial": "P.U.",
                    "last": "Srivastava"
                },
                {
                    "first": "John S.",
                    "initial": "J.S.",
                    "last": "Moran"
                },
                {
                    "first": "Benjamin",
                    "initial": "B.",
                    "last": "Schwartz"
                },
                {
                    "first": "Trudy V.",
                    "initial": "T.V.",
                    "last": "Murphy"
                }
            ],
            "firstpage": "1",
            "issn": "15458601",
            "lastpage": "34",
            "pmid": "16557217",
            "pub_year": 2006,
            "title": "Preventing tetanus, diphtheria, and pertussis among adolescents: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccines recommendations of the Advisory Committee on Immunization Practices (ACIP).",
            "volume": "55"
        },
        "b0050": {
            "authors": [],
            "firstpage": "468",
            "issn": "01492195",
            "lastpage": "470",
            "pmid": "22739778",
            "pub_year": 2012,
            "title": "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in adults aged 65 years and older - advisory committee on immunization practices (ACIP), 2012",
            "volume": "61"
        },
        "b0055": {
            "authors": [
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Sawyer"
                },
                {
                    "first": "Jennifer L.",
                    "initial": "J.L.",
                    "last": "Liang"
                },
                {
                    "first": "Nancy",
                    "initial": "N.",
                    "last": "Messonnier"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                }
            ],
            "firstpage": "131",
            "issn": "01492195",
            "lastpage": "135",
            "pmid": "23425962",
            "pub_year": 2013,
            "title": "Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women - Advisory committee on immunization practices (ACIP), 2012",
            "volume": "62"
        },
        "b0060": {
            "authors": [
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Esposito"
                },
                {
                    "first": "N.",
                    "initial": "N.",
                    "last": "Principi"
                },
                {
                    "first": null,
                    "initial": null,
                    "last": null
                }
            ],
            "doi": "10.1016/j.cmi.2016.01.003",
            "firstpage": "S89",
            "issn": "1198743X",
            "lastpage": "S95",
            "pmid": "27130670",
            "pub_year": 2016,
            "title": "Immunization against pertussis in adolescents and adults",
            "volume": "22"
        },
        "b0065": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Bartlett"
                },
                {
                    "first": "Ali",
                    "initial": "A.",
                    "last": "Rowhani-Rahbar"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Fireman"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                }
            ],
            "doi": "10.1056/NEJMoa1200850",
            "firstpage": "1012",
            "issn": "00284793",
            "lastpage": "1019",
            "pmid": "22970945",
            "pub_year": 2012,
            "title": "Waning protection after fifth dose of acellular pertussis vaccine in children",
            "volume": "367"
        },
        "b0070": {
            "authors": [
                {
                    "first": "Sara Y.",
                    "initial": "S.Y.",
                    "last": "Tartof"
                },
                {
                    "first": "Melissa",
                    "initial": "M.",
                    "last": "Lewis"
                },
                {
                    "first": "Cynthia",
                    "initial": "C.",
                    "last": "Kenyon"
                },
                {
                    "first": "Karen",
                    "initial": "K.",
                    "last": "White"
                },
                {
                    "first": "Andrew",
                    "initial": "A.",
                    "last": "Osborn"
                },
                {
                    "first": "Juventila",
                    "initial": "J.",
                    "last": "Liko"
                },
                {
                    "first": "Elizabeth",
                    "initial": "E.",
                    "last": "Zell"
                },
                {
                    "first": "Stacey",
                    "initial": "S.",
                    "last": "Martin"
                },
                {
                    "first": "Nancy E.",
                    "initial": "N.E.",
                    "last": "Messonnier"
                },
                {
                    "first": "Thomas A.",
                    "initial": "T.A.",
                    "last": "Clark"
                },
                {
                    "first": "Tami H.",
                    "initial": "T.H.",
                    "last": "Skoff"
                }
            ],
            "doi": "10.1542/peds.2012-1928",
            "firstpage": "e1047",
            "issn": "00314005",
            "lastpage": "e1052",
            "pmid": "23478868",
            "pub_year": 2013,
            "title": "Waning immunity to pertussis following 5 doses of DTaP",
            "volume": "131"
        },
        "b0075": {
            "authors": [
                {
                    "first": "Nicola P.",
                    "initial": "N.P.",
                    "last": "Klein"
                },
                {
                    "first": "Joan",
                    "initial": "J.",
                    "last": "Bartlett"
                },
                {
                    "first": "Bruce",
                    "initial": "B.",
                    "last": "Fireman"
                },
                {
                    "first": "Roger",
                    "initial": "R.",
                    "last": "Baxter"
                }
            ],
            "doi": "10.1542/peds.2015-3326",
            "issn": "00314005",
            "pmid": "26908667",
            "pub_year": 2016,
            "title": "Waning Tdap effectiveness in adolescents",
            "volume": "137"
        },
        "b0080": {
            "authors": [
                {
                    "first": "Saskia",
                    "initial": "S.",
                    "last": "van der Lee"
                },
                {
                    "first": "Debbie M.",
                    "initial": "D.M.",
                    "last": "van Rooijen"
                },
                {
                    "first": "Mary L\u00e8ne",
                    "initial": "M.L.",
                    "last": "de Zeeuw-Brouwer"
                },
                {
                    "first": "Marjan J.M.",
                    "initial": "M.J.M.",
                    "last": "Bogaard"
                },
                {
                    "first": "Pieter G.M.",
                    "initial": "P.G.M.",
                    "last": "van Gageldonk"
                },
                {
                    "first": "Axel Bonacic",
                    "initial": "A.B.",
                    "last": "Marinovic"
                },
                {
                    "first": "Elisabeth A.M.",
                    "initial": "E.A.M.",
                    "last": "Sanders"
                },
                {
                    "first": "Guy A.M.",
                    "initial": "G.A.M.",
                    "last": "Berbers"
                },
                {
                    "first": "Anne Marie",
                    "initial": "A.M.",
                    "last": "Buisman"
                }
            ],
            "doi": "10.3389/fimmu.2018.00681",
            "issn": "16643224",
            "pub_year": 2018,
            "title": "Robust humoral and cellular immune responses to pertussis in adults after a first acellular booster vaccination",
            "volume": "9"
        },
        "b0085": {
            "authors": [
                {
                    "first": "Vitali",
                    "initial": "V.",
                    "last": "Pool"
                },
                {
                    "first": "Antigona",
                    "initial": "A.",
                    "last": "Tomovici"
                },
                {
                    "first": "David R.",
                    "initial": "D.R.",
                    "last": "Johnson"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                }
            ],
            "doi": "10.1016/j.vaccine.2018.03.029",
            "firstpage": "2282",
            "issn": "0264410X",
            "lastpage": "2287",
            "pmid": "29573876",
            "pub_year": 2018,
            "title": "Humoral immunity 10\u202fyears after booster immunization with an adolescent and adult formulation combined tetanus, diphtheria, and 5-component acellular pertussis vaccine in the USA",
            "volume": "36"
        },
        "b0090": {
            "authors": [
                {
                    "first": "Mark",
                    "initial": "M.",
                    "last": "Blatter"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Wayde M.",
                    "initial": "W.M.",
                    "last": "Weston"
                },
                {
                    "first": "Ping",
                    "initial": "P.",
                    "last": "Li"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Howe"
                }
            ],
            "doi": "10.1016/j.vaccine.2008.11.028",
            "firstpage": "765",
            "issn": "0264410X",
            "lastpage": "772",
            "pmid": "19041352",
            "pub_year": 2009,
            "title": "Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age",
            "volume": "27"
        },
        "b0095": {
            "authors": [
                {
                    "first": "Wayde",
                    "initial": "W.",
                    "last": "Weston"
                },
                {
                    "first": "Marc",
                    "initial": "M.",
                    "last": "Messier"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Xiangfeng",
                    "initial": "X.",
                    "last": "Wu"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Howe"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.09.063",
            "firstpage": "8483",
            "issn": "0264410X",
            "lastpage": "8486",
            "pmid": "21945698",
            "pub_year": 2011,
            "title": "Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine",
            "volume": "29"
        },
        "b0100": {
            "authors": [
                {
                    "first": "H. J.",
                    "initial": "H.J.",
                    "last": "Schmitt"
                },
                {
                    "first": "A.",
                    "initial": "A.",
                    "last": "Schuind"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Knuf"
                },
                {
                    "first": "K.",
                    "initial": "K.",
                    "last": "Beutel"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Schulte-Wissermann"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Gahr"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Schult"
                },
                {
                    "first": "J.",
                    "initial": "J.",
                    "last": "Folkens"
                },
                {
                    "first": "W.",
                    "initial": "W.",
                    "last": "Rauh"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Bogaerts"
                },
                {
                    "first": "H. L.",
                    "initial": "H.L.",
                    "last": "Bork"
                },
                {
                    "first": "R.",
                    "initial": "R.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1016/S0022-3476(96)70152-X",
            "firstpage": "695",
            "issn": "00223476",
            "lastpage": "701",
            "pmid": "8917236",
            "pub_year": 1996,
            "title": "Clinical experience of a tricomponent acellular pertussis vaccine combined with diphtheria and tetanus toxoids for primary vaccination in 22,505 infants",
            "volume": "129"
        },
        "b0105": {
            "authors": [
                {
                    "first": "Martina",
                    "initial": "M.",
                    "last": "Kovac"
                },
                {
                    "first": "Lusin\u00e9",
                    "initial": "L.",
                    "last": "Kostanyan"
                },
                {
                    "first": "Narcisa",
                    "initial": "N.",
                    "last": "Mesaros"
                },
                {
                    "first": "Sherine",
                    "initial": "S.",
                    "last": "Kuriyakose"
                },
                {
                    "first": "Meera",
                    "initial": "M.",
                    "last": "Varman"
                }
            ],
            "doi": "10.1080/21645515.2018.1460292",
            "firstpage": "1977",
            "issn": "21645515",
            "lastpage": "1986",
            "pmid": "29630439",
            "pub_year": 2018,
            "title": "Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study",
            "volume": "14"
        },
        "b0110": {
            "authors": [
                {
                    "first": "Moira E.",
                    "initial": "M.E.",
                    "last": "Melville-Smith"
                },
                {
                    "first": "Valerie A.",
                    "initial": "V.A.",
                    "last": "Seagroatt"
                },
                {
                    "first": "Johanna T.",
                    "initial": "J.T.",
                    "last": "Watkins"
                }
            ],
            "doi": "10.1016/S0092-1157(83)80038-9",
            "firstpage": "137",
            "issn": "00921157",
            "lastpage": "144",
            "pmid": "6345548",
            "pub_year": 1983,
            "title": "A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera",
            "volume": "11"
        },
        "b0115": {
            "authors": [
                {
                    "first": "M. E.",
                    "initial": "M.E.",
                    "last": "Camargo"
                },
                {
                    "first": "L.",
                    "initial": "L.",
                    "last": "Silveira"
                },
                {
                    "first": "J. A.",
                    "initial": "J.A.",
                    "last": "Furuta"
                },
                {
                    "first": "E. P.",
                    "initial": "E.P.",
                    "last": "Oliveira"
                },
                {
                    "first": "O. A.",
                    "initial": "O.A.",
                    "last": "Germek"
                }
            ],
            "doi": "10.1128/jcm.20.4.772-774.1984",
            "firstpage": "772",
            "issn": "00951137",
            "lastpage": "774",
            "pmid": "6386879",
            "pub_year": 1984,
            "title": "Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum",
            "volume": "20"
        },
        "b0120": {
            "authors": [
                {
                    "first": "K. F.",
                    "initial": "K.F.",
                    "last": "Karpinski"
                },
                {
                    "first": "S.",
                    "initial": "S.",
                    "last": "Hayward"
                },
                {
                    "first": "H.",
                    "initial": "H.",
                    "last": "Tryphonas"
                }
            ],
            "doi": "10.1016/0022-1759(87)90289-4",
            "firstpage": "189",
            "issn": "00221759",
            "lastpage": "194",
            "pmid": "3668258",
            "pub_year": 1987,
            "title": "Statistical considerations in the quantitation of serum immunoglobulin levels using the Enzyme-Linked Immunosorbent Assay (ELISA)",
            "volume": "103"
        },
        "b0125": {
            "authors": [
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Granstr\u00f6m"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Thor\u00e9n"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Blennow"
                },
                {
                    "first": "M.",
                    "initial": "M.",
                    "last": "Tiru"
                },
                {
                    "first": "Y.",
                    "initial": "Y.",
                    "last": "Sato"
                }
            ],
            "doi": "10.1007/BF02097184",
            "firstpage": "18",
            "issn": "07222211",
            "lastpage": "21",
            "pmid": "2883004",
            "pub_year": 1987,
            "title": "Acellular pertussis vaccine in adults: Adverse reactions and immune response",
            "volume": "6"
        },
        "b0130": {
            "authors": [
                {
                    "first": "Robert",
                    "initial": "R.",
                    "last": "Booy"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Van Der Meeren"
                },
                {
                    "first": "Su Peing",
                    "initial": "S.P.",
                    "last": "Ng"
                },
                {
                    "first": "Froilan",
                    "initial": "F.",
                    "last": "Celzo"
                },
                {
                    "first": "Gunasekaran",
                    "initial": "G.",
                    "last": "Ramakrishnan"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.1016/j.vaccine.2010.10.025",
            "firstpage": "45",
            "issn": "0264410X",
            "lastpage": "50",
            "pmid": "20974302",
            "pub_year": 2010,
            "title": "A decennial booster dose of reduced antigen content diphtheria, tetanus, acellular pertussis vaccine (Boostrix\u2122) is immunogenic and well tolerated in adults",
            "volume": "29"
        },
        "b0135": {
            "authors": [
                {
                    "first": "Heinz J.",
                    "initial": "H.J.",
                    "last": "Schmitt"
                },
                {
                    "first": "Carl H.Wirsing",
                    "initial": "C.H.W.",
                    "last": "Von K\u00f6nig"
                },
                {
                    "first": "Albrecht",
                    "initial": "A.",
                    "last": "Neiss"
                },
                {
                    "first": "Hugues",
                    "initial": "H.",
                    "last": "Bogaerts"
                },
                {
                    "first": "Hans L.",
                    "initial": "H.L.",
                    "last": "Bock"
                },
                {
                    "first": "Hermann",
                    "initial": "H.",
                    "last": "Schulte-Wissermann"
                },
                {
                    "first": "Manfred",
                    "initial": "M.",
                    "last": "Gahr"
                },
                {
                    "first": "Rainer",
                    "initial": "R.",
                    "last": "Schult"
                },
                {
                    "first": "Jens U.",
                    "initial": "J.U.",
                    "last": "Folkens"
                },
                {
                    "first": "Wolfgang",
                    "initial": "W.",
                    "last": "Rauh"
                },
                {
                    "first": "Ralf",
                    "initial": "R.",
                    "last": "Clemens"
                }
            ],
            "doi": "10.1001/jama.275.1.37",
            "firstpage": "37",
            "issn": "00987484",
            "lastpage": "41",
            "pmid": "8531284",
            "pub_year": 1996,
            "title": "Efficacy of acellular pertussis vaccine in early childhood after household exposure",
            "volume": "275"
        },
        "b0140": {
            "authors": [
                {
                    "first": "Michael E.",
                    "initial": "M.E.",
                    "last": "Pichichero"
                },
                {
                    "first": "Mark M.",
                    "initial": "M.M.",
                    "last": "Blatter"
                },
                {
                    "first": "William A.",
                    "initial": "W.A.",
                    "last": "Kennedy"
                },
                {
                    "first": "James",
                    "initial": "J.",
                    "last": "Hedrick"
                },
                {
                    "first": "Dominique",
                    "initial": "D.",
                    "last": "Descamps"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                }
            ],
            "doi": "10.1542/peds.2005-1759",
            "firstpage": "1084",
            "issn": "00314005",
            "lastpage": "1093",
            "pmid": "16585302",
            "pub_year": 2006,
            "title": "Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents",
            "volume": "117"
        },
        "b0145": {
            "authors": [
                {
                    "first": "Corinne",
                    "initial": "C.",
                    "last": "Vandermeulen"
                },
                {
                    "first": "Heidi",
                    "initial": "H.",
                    "last": "Theeten"
                },
                {
                    "first": "Niraj",
                    "initial": "N.",
                    "last": "Rathi"
                },
                {
                    "first": "Sherine",
                    "initial": "S.",
                    "last": "Kuriyakose"
                },
                {
                    "first": "Htay Htay",
                    "initial": "H.H.",
                    "last": "Han"
                },
                {
                    "first": "Etienne",
                    "initial": "E.",
                    "last": "Sokal"
                },
                {
                    "first": "Karel",
                    "initial": "K.",
                    "last": "Hoppenbrouwers"
                },
                {
                    "first": "Pierre",
                    "initial": "P.",
                    "last": "Van Damme"
                }
            ],
            "doi": "10.1016/j.vaccine.2014.10.049",
            "firstpage": "3026",
            "issn": "0264410X",
            "lastpage": "3034",
            "pmid": "25613716",
            "pub_year": 2015,
            "title": "Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium",
            "volume": "33"
        },
        "b0150": {
            "authors": [
                {
                    "first": "Scott A.",
                    "initial": "S.A.",
                    "last": "Halperin"
                },
                {
                    "first": "Catherine",
                    "initial": "C.",
                    "last": "Donovan"
                },
                {
                    "first": "Gary S.",
                    "initial": "G.S.",
                    "last": "Marshall"
                },
                {
                    "first": "Vitali",
                    "initial": "V.",
                    "last": "Pool"
                },
                {
                    "first": "Michael D.",
                    "initial": "M.D.",
                    "last": "Decker"
                },
                {
                    "first": "David R.",
                    "initial": "D.R.",
                    "last": "Johnson"
                },
                {
                    "first": "David P.",
                    "initial": "D.P.",
                    "last": "Greenberg"
                },
                {
                    "first": "Gerald",
                    "initial": "G.",
                    "last": "Bader"
                },
                {
                    "first": "Stuart",
                    "initial": "S.",
                    "last": "Weisman"
                },
                {
                    "first": "Ambaram",
                    "initial": "A.",
                    "last": "Chauhan"
                },
                {
                    "first": "Kenneth",
                    "initial": "K.",
                    "last": "Bromberg"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "McGuire"
                },
                {
                    "first": "Martin L.",
                    "initial": "M.L.",
                    "last": "Kabongo"
                },
                {
                    "first": "Matthew",
                    "initial": "M.",
                    "last": "Hall"
                },
                {
                    "first": "Leonard",
                    "initial": "L.",
                    "last": "Weiner"
                },
                {
                    "first": "Peter",
                    "initial": "P.",
                    "last": "Silas"
                },
                {
                    "first": "Daniel",
                    "initial": "D.",
                    "last": "Brune"
                },
                {
                    "first": "Tim",
                    "initial": "T.",
                    "last": "Craig"
                },
                {
                    "first": "Marion",
                    "initial": "M.",
                    "last": "Michaels"
                },
                {
                    "first": "Edwin",
                    "initial": "E.",
                    "last": "Anderson"
                },
                {
                    "first": "Susan",
                    "initial": "S.",
                    "last": "Keathley"
                },
                {
                    "first": "Kevin",
                    "initial": "K.",
                    "last": "Rouse"
                },
                {
                    "first": "Joseph",
                    "initial": "J.",
                    "last": "Leader"
                },
                {
                    "first": "Laura",
                    "initial": "L.",
                    "last": "Helman"
                },
                {
                    "first": "Wilson",
                    "initial": "W.",
                    "last": "Andrews"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Bernstein"
                },
                {
                    "first": "Randall",
                    "initial": "R.",
                    "last": "Middleton"
                },
                {
                    "first": "Mahashweta",
                    "initial": "M.",
                    "last": "Ghosh"
                },
                {
                    "first": "Douglas",
                    "initial": "D.",
                    "last": "Mitchell"
                },
                {
                    "first": "Shelly",
                    "initial": "S.",
                    "last": "Senders"
                },
                {
                    "first": "Wilson",
                    "initial": "W.",
                    "last": "Andrews"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Wyszomierski"
                },
                {
                    "first": "David",
                    "initial": "D.",
                    "last": "Allison"
                }
            ],
            "doi": "10.1093/jpids/pix113",
            "firstpage": "105",
            "issn": "20487193",
            "lastpage": "114",
            "pmid": "29438562",
            "pub_year": 2019,
            "title": "Randomized controlled trial of the safety and immunogenicity of revaccination with tetanus-diphtheria-acellular pertussis vaccine (TDAP) in adults 10 years after a previous dose",
            "volume": "8"
        },
        "b0155": {
            "authors": [
                {
                    "first": "Birgit",
                    "initial": "B.",
                    "last": "Weinberger"
                },
                {
                    "first": "Michael",
                    "initial": "M.",
                    "last": "Schirmer"
                },
                {
                    "first": "Raffaella Matteucci",
                    "initial": "R.M.",
                    "last": "Gothe"
                },
                {
                    "first": "Uwe",
                    "initial": "U.",
                    "last": "Siebert"
                },
                {
                    "first": "Dietmar",
                    "initial": "D.",
                    "last": "Fuchs"
                },
                {
                    "first": "Beatrix",
                    "initial": "B.",
                    "last": "Grubeck-Loebenstein"
                }
            ],
            "doi": "10.1371/journal.pone.0082967",
            "issn": "19326203",
            "pmid": "24349407",
            "pub_year": 2013,
            "title": "Recall responses to tetanus and diphtheria vaccination are frequently insufficient in elderly persons",
            "volume": "8"
        },
        "b0160": {
            "authors": [
                {
                    "first": "Jussi",
                    "initial": "J.",
                    "last": "Mertsola"
                },
                {
                    "first": "Olivier",
                    "initial": "O.",
                    "last": "Van Der Meeren"
                },
                {
                    "first": "Qiushui",
                    "initial": "Q.",
                    "last": "He"
                },
                {
                    "first": "Anna",
                    "initial": "A.",
                    "last": "Linko-Parvinen"
                },
                {
                    "first": "Gunasekaran",
                    "initial": "G.",
                    "last": "Ramakrishnan"
                },
                {
                    "first": "Leni",
                    "initial": "L.",
                    "last": "Mannermaa"
                },
                {
                    "first": "Maaria",
                    "initial": "M.",
                    "last": "Soila"
                },
                {
                    "first": "Markku",
                    "initial": "M.",
                    "last": "Pulkkinen"
                },
                {
                    "first": "Jeanne Marie",
                    "initial": "J.M.",
                    "last": "Jacquet"
                }
            ],
            "doi": "10.1086/655825",
            "firstpage": "656",
            "issn": "10584838",
            "lastpage": "662",
            "pmid": "20704493",
            "pub_year": 2010,
            "title": "Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults",
            "volume": "51"
        },
        "b0165": {
            "authors": [
                {
                    "first": "Wayde M.",
                    "initial": "W.M.",
                    "last": "Weston"
                },
                {
                    "first": "Leonard R.",
                    "initial": "L.R.",
                    "last": "Friedland"
                },
                {
                    "first": "Xiangfeng",
                    "initial": "X.",
                    "last": "Wu"
                },
                {
                    "first": "Barbara",
                    "initial": "B.",
                    "last": "Howe"
                }
            ],
            "doi": "10.1016/j.vaccine.2011.12.055",
            "firstpage": "1721",
            "issn": "0264410X",
            "lastpage": "1728",
            "pmid": "22212127",
            "pub_year": 2012,
            "title": "Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix \u00ae): Results of two randomized trials",
            "volume": "30"
        },
        "b0170": null,
        "b0175": {
            "authors": [
                {
                    "first": "Soju",
                    "initial": "S.",
                    "last": "Chang"
                },
                {
                    "first": "Patrick M.",
                    "initial": "P.M.",
                    "last": "O'Connor"
                },
                {
                    "first": "Barbara A.",
                    "initial": "B.A.",
                    "last": "Slade"
                },
                {
                    "first": "Emily Jane",
                    "initial": "E.J.",
                    "last": "Woo"
                }
            ],
            "doi": "10.1016/j.vaccine.2012.10.097",
            "firstpage": "1447",
            "issn": "0264410X",
            "lastpage": "1452",
            "pmid": "23142308",
            "pub_year": 2013,
            "title": "U.S. Postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005-2007",
            "volume": "31"
        }
    },
    "body_text": [
        {
            "endOffset": 45248,
            "parents": [],
            "secId": "s0065",
            "sentence": "Only 1 SAE, not related to vaccination, was reported in the group receiving Tdap-B as the first Tdap dose.",
            "startOffset": 45142,
            "title": "Discussion"
        },
        {
            "endOffset": 24185,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 24184,
                    "startOffset": 24180
                }
            },
            "secId": "s0005",
            "sentence": "In an extension study, we demonstrated that immune responses to vaccine antigens persisted up to 3 years after vaccination [19].",
            "startOffset": 24057,
            "title": "Introduction"
        },
        {
            "endOffset": 35315,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The percentage of participants with anti-PT, anti-FHA and anti-PRN antibody concentrations above the assay cut-offs were \u226598.8%, 100% and 100%, respectively for all 3 groups (Table 3).",
            "startOffset": 35131,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 27544,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The second co-primary objective, evaluated at the Year 9 timepoint, was to demonstrate that the immune response elicited by a second dose of Tdap vaccine (Tdap-B and Tdap-A groups) was non-inferior to that elicited by a first dose of Tdap-B vaccine (Control group), with respect to seroprotection rates against diphtheria and tetanus, one month following vaccination with Tdap.",
            "startOffset": 27167,
            "title": "Study objectives"
        },
        {
            "endOffset": 38455,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At least one unsolicited AE considered by the investigator as vaccination-related was reported for 14 (4.5%) participants in the Tdap-B group, 3 (2.2%) participants in the Tdap-A group and 4 (1.1%) participants in the Control group.",
            "startOffset": 38223,
            "title": "Safety"
        },
        {
            "endOffset": 34132,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Antibody GMCs for the 3 antigens tended to decrease from Year 5 to Year 9, but remained comparable or higher than the pre-initial vaccination levels.",
            "startOffset": 33983,
            "title": "Persistence of immune response"
        },
        {
            "endOffset": 40678,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 40677,
                    "startOffset": 40664
                },
                "b0105": {
                    "endOffset": 40677,
                    "startOffset": 40664
                },
                "b0130": {
                    "endOffset": 40677,
                    "startOffset": 40664
                },
                "b0140": {
                    "endOffset": 40677,
                    "startOffset": 40664
                }
            },
            "secId": "s0065",
            "sentence": "In this approach, the efficacy of DTaP was extrapolated from infants to adults, as previously successfully done in several other studies [19,21,26,28].",
            "startOffset": 40527,
            "title": "Discussion"
        },
        {
            "endOffset": 36666,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "GMC ratios between groups for all antigens one month after booster vaccination were between 0.66 and 1.21 for Tdap-B group over Control group and 0.68 and 1.52 for Tdap-A group over Control group (Table S3).",
            "startOffset": 36459,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 37491,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The incidence of solicited local AEs was higher in the Tdap groups than in the Control group.",
            "startOffset": 37398,
            "title": "Safety"
        },
        {
            "endOffset": 45892,
            "parents": [],
            "secId": "s0065",
            "sentence": "The study was also limited by the low power to assess non-inferiority objectives in terms of booster responses.",
            "startOffset": 45781,
            "title": "Discussion"
        },
        {
            "endOffset": 21966,
            "parents": [],
            "secId": "s0005",
            "sentence": "Combined vaccines containing reduced-antigen-content of diphtheria toxoid, tetanus toxoid, and acellular pertussis (Tdap) have been available for more than a decade and are included as booster vaccinations in immunization schedules for children, adolescents and adults in developed countries worldwide.",
            "startOffset": 21664,
            "title": "Introduction"
        },
        {
            "endOffset": 29562,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "At Year 9, the new assay cut-offs were 0.057 IU/mL for diphtheria, 0.043 IU/mL for tetanus, 2.693 IU/mL for PT, 2.046 IU/mL for FHA and 2.187 IU/mL for PRN.",
            "startOffset": 29406,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 38853,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Injection site bruising (in 3 [1.0%] participants in Tdap-B group and 1 [0.7%] participant in Tdap-A group) and injection site pruritus (4 [1.3%] participants in Tdap-B group) were the most reported unsolicited AEs.",
            "startOffset": 38638,
            "title": "Safety"
        },
        {
            "endOffset": 45141,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 45140,
                    "startOffset": 45133
                },
                "b0160": {
                    "endOffset": 45140,
                    "startOffset": 45133
                }
            },
            "secId": "s0065",
            "sentence": "However, a higher incidence of solicited local AEs was observed in participants having received 2 sequential Tdap booster doses compared to the Control group, consistent with previous reports of a higher local reactogenicity in adults receiving a decennial booster dose versus one booster dose administered 10 years earlier [26,32].",
            "startOffset": 44809,
            "title": "Discussion"
        },
        {
            "endOffset": 22973,
            "parents": [],
            "refoffsets": {
                "b0075": {
                    "endOffset": 22972,
                    "startOffset": 22968
                }
            },
            "secId": "s0005",
            "sentence": "In teenagers vaccinated with acellular pertussis vaccines, a routine Tdap dose administered at 11\u201312 years of age provided moderate protection against pertussis in the first year post-vaccination, which then declined substantially within 4 years after vaccination [15].",
            "startOffset": 22704,
            "title": "Introduction"
        },
        {
            "endOffset": 26502,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Written informed consent was obtained from each participant prior to each timepoint of the extension trial.",
            "startOffset": 26395,
            "title": "Study design and participants"
        },
        {
            "endOffset": 41136,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, the failure to meet non-inferiority margins has most likely no clinical relevance, since a very stringent definition of booster response was used and higher pre-vaccination antibody levels were observed in the Tdap groups (receiving a prior booster dose) compared with the Control group.",
            "startOffset": 40840,
            "title": "Discussion"
        },
        {
            "endOffset": 21664,
            "parents": [],
            "refoffsets": {
                "b0040": {
                    "endOffset": 21663,
                    "startOffset": 21660
                }
            },
            "secId": "s0005",
            "sentence": "In the United States (US), in 2016, the estimated number of pertussis cases was 15,737, of which 5237 (33.3%) were reported in 11\u201319 year-olds and 3478 (22.1%) in adults >20 years of age [8].",
            "startOffset": 21473,
            "title": "Introduction"
        },
        {
            "endOffset": 43907,
            "parents": [],
            "secId": "s0065",
            "sentence": "Although these comparisons are limited by the fact that different cut-offs for seropositivity were used across studies, they seem to indicate that immunity against PT wanes more rapidly than for FHA and PRN and the decline in anti-PT antibody levels also increases with age at vaccination with a steeper decrease at older age, due to weakening of the immune system.",
            "startOffset": 43542,
            "title": "Discussion"
        },
        {
            "endOffset": 42835,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 42834,
                    "startOffset": 42827
                },
                "b0150": {
                    "endOffset": 42834,
                    "startOffset": 42827
                }
            },
            "secId": "s0065",
            "sentence": "Similarly to our study, seroprotective levels were restored in all participants following the administration of a second Tdap-A booster dose [17,30].",
            "startOffset": 42686,
            "title": "Discussion"
        },
        {
            "endOffset": 44808,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 44782,
                    "startOffset": 44778
                },
                "b0165": {
                    "endOffset": 44794,
                    "startOffset": 44790
                }
            },
            "secId": "s0065",
            "sentence": "Following administration of a Tdap-B dose at Year 9, the overall incidence of AEs was similar between groups receiving it as a booster or an initial dose and in line with previously reported results for Tdap-B in adults <65 [18] or \u226565 [33] years of age.",
            "startOffset": 44554,
            "title": "Discussion"
        },
        {
            "endOffset": 21472,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21373,
                    "startOffset": 21366
                },
                "b0020": {
                    "endOffset": 21373,
                    "startOffset": 21366
                },
                "b0025": {
                    "endOffset": 21373,
                    "startOffset": 21366
                },
                "b0030": {
                    "endOffset": 21412,
                    "startOffset": 21407
                },
                "b0035": {
                    "endOffset": 21412,
                    "startOffset": 21407
                }
            },
            "secId": "s0005",
            "sentence": "However, a higher pertussis prevalence [1,4,5] and a lower vaccination coverage [6,7] are reported in older age groups than in young individuals.",
            "startOffset": 21327,
            "title": "Introduction"
        },
        {
            "endOffset": 30593,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assuming that \u223c1100 participants (of whom 733 in the Tdap-B group) would return for the Year 9 follow-up, a sample size of 367 participants was calculated for enrollment in the Control group.",
            "startOffset": 30402,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 39741,
            "parents": [],
            "secId": "s0065",
            "sentence": "Comparison at Year 9 was hindered by changes in the assay cut-off, but antibody GMCs for all 3 pertussis antigens remained similar or higher than those observed prior to initial vaccination with either the Tdap-B or Tdap-A vaccine.",
            "startOffset": 39510,
            "title": "Discussion"
        },
        {
            "endOffset": 33223,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At Year 5, seroprotection rates were \u226598.4% for diphtheria and \u226598.0% for tetanus, in both Tdap groups.",
            "startOffset": 33120,
            "title": "Persistence of immune response"
        },
        {
            "endOffset": 22528,
            "parents": [],
            "refoffsets": {
                "b0060": {
                    "endOffset": 22527,
                    "startOffset": 22523
                }
            },
            "secId": "s0005",
            "sentence": "The recorded increase in pertussis incidence is caused by a variety of factors, including changes in disease epidemiology, improvements in the case definition and methods to identify cases or emergence of modified Bordetella pertussis strains [12].",
            "startOffset": 22280,
            "title": "Introduction"
        },
        {
            "endOffset": 45366,
            "parents": [],
            "refoffsets": {
                "b0170": {
                    "endOffset": 45308,
                    "startOffset": 45304
                },
                "b0175": {
                    "endOffset": 45332,
                    "startOffset": 45328
                }
            },
            "secId": "s0065",
            "sentence": "Overall, the incidence of AEs was consistent with pre- [34] and post-licensure [35] safety data for Tdap vaccination.",
            "startOffset": 45249,
            "title": "Discussion"
        },
        {
            "endOffset": 39113,
            "parents": [],
            "secId": "s0065",
            "sentence": "Immune responses to diphtheria and tetanus elicited by Tdap vaccination were persistent at Years 5 and 9.",
            "startOffset": 39008,
            "title": "Discussion"
        },
        {
            "endOffset": 25711,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 25710,
                    "startOffset": 25706
                }
            },
            "secId": "s0015",
            "sentence": "The vaccine composition was previously described [18].",
            "startOffset": 25657,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24659,
            "parents": [],
            "secId": "s0005",
            "sentence": "Here we present antibody persistence at 5 and 9 years following Tdap vaccination in the initial study and the immunogenicity and safety of a second Tdap-B booster dose administered 9 years after the initial Tdap dose.",
            "startOffset": 24442,
            "title": "Introduction"
        },
        {
            "endOffset": 28423,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Non-inferiority was demonstrated if the LLs of the 97.5% CI for the geometric mean antibody concentrations (GMC) ratios (Tdap-B or Tdap-A group over DTPa) were \u22650.67, for PTFHAPRN.",
            "startOffset": 28243,
            "title": "Study objectives"
        },
        {
            "endOffset": 30853,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Assuming that 80% of enrolled participants would be evaluable, the power to conclude on the second and third co-primary objectives simultaneously at Year 9 was 97.9% and 88.9% for non-inferiority assessments conducted in Tdap-B and Tdap-A groups, respectively.",
            "startOffset": 30593,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 29937,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0120": {
                    "endOffset": 29881,
                    "startOffset": 29874
                },
                "b0125": {
                    "endOffset": 29881,
                    "startOffset": 29874
                }
            },
            "secId": "s0025",
            "sentence": "As no correlate of protection is defined for pertussis antigens [24,25], the ELISA cut-offs were used to define seropositivity.",
            "startOffset": 29810,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 42221,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 42117,
                    "startOffset": 42113
                },
                "b0150": {
                    "endOffset": 42220,
                    "startOffset": 42216
                }
            },
            "secId": "s0065",
            "sentence": "However, in a previous trial in healthy US adults aged 18\u2013<65 years, all participants maintained seroprotective antibody levels for tetanus, but only 84.6% also had seroprotective levels for diphtheria 10 years post-vaccination with a booster dose of Tdap-A [17], very similar to other studies in Canadian and US adults, 8\u201312 years post-vaccination with Tdap-A [30].",
            "startOffset": 41855,
            "title": "Discussion"
        },
        {
            "endOffset": 22703,
            "parents": [],
            "refoffsets": {
                "b0065": {
                    "endOffset": 22702,
                    "startOffset": 22695
                },
                "b0070": {
                    "endOffset": 22702,
                    "startOffset": 22695
                }
            },
            "secId": "s0005",
            "sentence": "However, several studies have shown that protection against pertussis wanes within 5 years following the completion of the 5-dose vaccination schedule during infancy [13,14].",
            "startOffset": 22529,
            "title": "Introduction"
        },
        {
            "endOffset": 40526,
            "parents": [],
            "secId": "s0065",
            "sentence": "Since there are no established correlates of protection for pertussis, an immuno-bridging approach was used to assess immune responses to pertussis antigens following vaccination with Tdap.",
            "startOffset": 40337,
            "title": "Discussion"
        },
        {
            "endOffset": 31487,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The safety analysis was performed on all participants vaccinated at the Year 9 timepoint.",
            "startOffset": 31398,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 43023,
            "parents": [],
            "secId": "s0065",
            "sentence": "In our study, antibody levels against pertussis antigens, and in particular against PT, seemed to wane more rapidly than for diphtheria and tetanus, which is in line with previous reports.",
            "startOffset": 42835,
            "title": "Discussion"
        },
        {
            "endOffset": 46513,
            "parents": [],
            "secId": "s0070",
            "sentence": "These results, together with long-term antibody persistence data, support the administration of Tdap-B as a decennial booster dose.",
            "startOffset": 46382,
            "title": "Conclusions"
        },
        {
            "endOffset": 32140,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Seroprotection/seropositivity rates, GMCs, booster and alternate booster (i.e., taking into account pre-vaccination levels) response rates and the percentage of participants reporting (S)AEs were calculated with 95% CIs.",
            "startOffset": 31920,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 26178,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy adults who received vaccination in the initial study were eligible to participate in the extension study.",
            "startOffset": 26065,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37837,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Grade 3 pain was reported for 3 (1.0%) participants in the Tdap-B group, 1 (0.7%) participant in Tdap-A group and 4 (1.1%) participants in the Control group (Fig. 2A).",
            "startOffset": 37670,
            "title": "Safety"
        },
        {
            "endOffset": 42685,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 42684,
                    "startOffset": 42680
                }
            },
            "secId": "s0065",
            "sentence": "A more pronounced decline was also observed for diphtheria over a 10-year period in adults receiving a Tdap-A booster vaccination at 8\u2013<64 years old than in adolescents boosted at 11\u201317 years of age [17].",
            "startOffset": 42481,
            "title": "Discussion"
        },
        {
            "endOffset": 25656,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "At Year 9, all willing participants received a booster dose (0.5 mL) of Tdap-B (lots AC52VB117B, AC52VB118A, AC52VB151C) administered intramuscularly into the deltoid of the non-dominant arm.",
            "startOffset": 25465,
            "title": "Study design and participants"
        },
        {
            "endOffset": 39509,
            "parents": [],
            "refoffsets": {
                "b0095": {
                    "endOffset": 39508,
                    "startOffset": 39504
                }
            },
            "secId": "s0065",
            "sentence": "Antibody levels for pertussis components seemed to wane more rapidly, especially for PT, in line with results at Year 3 [19].",
            "startOffset": 39384,
            "title": "Discussion"
        },
        {
            "endOffset": 29340,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Up to Year 5, the ELISA cut-offs were 0.1 IU/mL for diphtheria and tetanus and 5 ELISA units/mL for pertussis components.",
            "startOffset": 29219,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 40336,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 40090,
                    "startOffset": 40083
                },
                "b0130": {
                    "endOffset": 40090,
                    "startOffset": 40083
                },
                "b0135": {
                    "endOffset": 40335,
                    "startOffset": 40331
                }
            },
            "secId": "s0065",
            "sentence": "Moreover, as previously reported for administration of a single Tdap booster dose [18,26], the immune response elicited by 2 Tdap doses was shown to be non-inferior to that induced by 3 DTPa doses administered during infancy in a household contact study in Germany which demonstrated the vaccine\u2019s high efficacy against pertussis [27].",
            "startOffset": 40001,
            "title": "Discussion"
        },
        {
            "endOffset": 31707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Seroprotection/seropositivity rates, GMCs, booster and alternate booster (i.e., taking into account pre-vaccination levels) response rates and the percentage of participants reporting (S)AEs were calculated with 95% CIs.",
            "startOffset": 31487,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 31191,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Persistence was analyzed in the according-to-protocol (ATP) cohorts, consisting of evaluable participants who attended the visit at Year 5 and 9, respectively.",
            "startOffset": 31032,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 46381,
            "parents": [],
            "secId": "s0070",
            "sentence": "A second dose of Tdap-B administered in adults at 9 years after initial Tdap vaccination is immunogenic and well-tolerated.",
            "startOffset": 46258,
            "title": "Conclusions"
        },
        {
            "endOffset": 36458,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In exploratory analyses, similar percentages of participants with alternate booster response were observed in the 2 Tdap groups (Table S2).",
            "startOffset": 36319,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 35477,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Booster response rates in the Tdap groups were \u226560.2% for diphtheria, \u226536.7% for tetanus and ranged from 77.5% to 96.7% for pertussis antigens (Table 2, Fig. S1).",
            "startOffset": 35315,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 25465,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 25360,
                    "startOffset": 25356
                },
                "b0095": {
                    "endOffset": 25371,
                    "startOffset": 25367
                }
            },
            "secId": "s0015",
            "sentence": "Results at Year 1 [18] and 3 [19] follow-up were previously described; here we present results for the Year 5 and 9 timepoints.",
            "startOffset": 25338,
            "title": "Study design and participants"
        },
        {
            "endOffset": 36189,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The non-inferiority margins for the difference between groups in the booster response rate (Tdap-B or Tdap-A minus Control group) were met only for PT in the Tdap-B group and FHA in the Tdap-A group (Table 2).",
            "startOffset": 35980,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 43541,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 43540,
                    "startOffset": 43536
                }
            },
            "secId": "s0065",
            "sentence": "In a different study in young adults vaccinated with Tdap-B 10 years earlier, seropositive levels were observed in \u226582.8% of participants for PT and all participants for FHA and PRN, regardless of the aluminium content [29].",
            "startOffset": 43317,
            "title": "Discussion"
        },
        {
            "endOffset": 33982,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At Year 9, similar percentages of seropositive participants were observed in the Tdap groups for all pertussis antigens (\u226584.9% for PT, \u226599.2% for FHA and \u226598.5% for PRN) (Table 1).",
            "startOffset": 33801,
            "title": "Persistence of immune response"
        },
        {
            "endOffset": 42480,
            "parents": [],
            "refoffsets": {
                "b0155": {
                    "endOffset": 42479,
                    "startOffset": 42475
                }
            },
            "secId": "s0065",
            "sentence": "The decline in seroprotective levels in time was found to increase with age: in >60-year-olds receiving vaccination against tetanus, diphtheria, pertussis and polio, 10% and 45% were not protected for tetanus and diphtheria, respectively, 5 years later [31].",
            "startOffset": 42222,
            "title": "Discussion"
        },
        {
            "endOffset": 33087,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The demographic characteristics at each timepoint are presented in Table S1.",
            "startOffset": 33011,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 29707,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "In addition, a Vero cell neutralization assay, with a cut-off of 0.016 IU/mL, was performed for samples with concentrations <0.1 IU/mL by ELISA.",
            "startOffset": 29563,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 22280,
            "parents": [],
            "refoffsets": {
                "b0050": {
                    "endOffset": 22191,
                    "startOffset": 22187
                },
                "b0055": {
                    "endOffset": 22279,
                    "startOffset": 22275
                }
            },
            "secId": "s0005",
            "sentence": "Routine vaccination is also recommended for all adults \u226519 years of age who have not received a dose of Tdap [10], for all pregnant women and for postpartum mothers not vaccinated during pregnancy [11].",
            "startOffset": 22078,
            "title": "Introduction"
        },
        {
            "endOffset": 40000,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 39999,
                    "startOffset": 39995
                }
            },
            "secId": "s0065",
            "sentence": "Non-inferiority of the immune response to diphtheria and tetanus of 2 Tdap doses administered 9 years apart versus the administration of 1 Tdap-B dose was demonstrated, regardless of the vaccine received as primary dose, consistent with previous reports [21].",
            "startOffset": 39741,
            "title": "Discussion"
        },
        {
            "endOffset": 29218,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Antibody concentrations against vaccine antigens were assessed using an enzyme-linked immunosorbent assay (ELISA) at GSK Biologicals laboratories.",
            "startOffset": 29072,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32759,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "In total, 1257 participants (856 in the Tdap-B group and 401 in the Tdap-A group) were included in the Year 5 cohort.",
            "startOffset": 32642,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 30401,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "No sample size was calculated for the Year 5 timepoint.",
            "startOffset": 30346,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 44554,
            "parents": [],
            "refoffsets": {
                "b0160": {
                    "endOffset": 44553,
                    "startOffset": 44549
                }
            },
            "secId": "s0065",
            "sentence": "However, in a decennial study conducted in Finland, booster response rates were similar for the pertussis antigens: PT (98.6%), FHA (97.3%) and PRN (93.2%) [32].",
            "startOffset": 44393,
            "title": "Discussion"
        },
        {
            "endOffset": 29072,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Blood samples (\u223c5 mL) were collected at Year 5 and pre- and post-vaccination at Year 9 (Fig. 1).",
            "startOffset": 28976,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 46096,
            "parents": [],
            "secId": "s0065",
            "sentence": "Although a higher-than-expected number of participants were lost to follow-up from vaccination in the initial study to Year 9, a sensitivity analysis showed that immunogenicity results were not impacted.",
            "startOffset": 45893,
            "title": "Discussion"
        },
        {
            "endOffset": 44079,
            "parents": [],
            "refoffsets": {
                "b0105": {
                    "endOffset": 44078,
                    "startOffset": 44074
                }
            },
            "secId": "s0065",
            "sentence": "Following administration of 2 Tdap-B doses 9 years apart, booster responses to pertussis antigens were more robust for PT and FHA than for PRN, as observed previously [21].",
            "startOffset": 43907,
            "title": "Discussion"
        },
        {
            "endOffset": 29809,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0110": {
                    "endOffset": 29808,
                    "startOffset": 29801
                },
                "b0115": {
                    "endOffset": 29808,
                    "startOffset": 29801
                }
            },
            "secId": "s0025",
            "sentence": "For diphtheria and tetanus, antibody concentrations \u22650.1 IU/mL were considered as protective [22,23].",
            "startOffset": 29708,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 32867,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "At Year 9, 809 of the 1071 participants (362 newly-enrolled in the Control group) were vaccinated (Fig. 1).",
            "startOffset": 32760,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 38223,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Fatigue was reported with higher frequency in the Tdap-B group compared to the Control group (Fig. 2B).",
            "startOffset": 38120,
            "title": "Safety"
        },
        {
            "endOffset": 33469,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "Antibody GMCs for tetanus tended to be higher in group Tdap-A compared with Tdap-B at both timepoints (Table 1).",
            "startOffset": 33357,
            "title": "Persistence of immune response"
        },
        {
            "endOffset": 38997,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "One SAE (nervous system disorders/seizure) was reported in the Control group, but was not considered by the investigator as vaccination-related.",
            "startOffset": 38853,
            "title": "Safety"
        },
        {
            "endOffset": 31920,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Additionally, a sensitivity analysis was performed to evaluate the robustness of GMC results with respect to drop-out from the initial study and exploratory between-group comparisons were conducted (see Text S2).",
            "startOffset": 31708,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 34721,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Non-inferiority margins were also met for the second co-primary objective (Table 2).",
            "startOffset": 34637,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 27053,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The first co-primary objective of the study evaluated the persistence of antibodies against diphtheria and tetanus at 5 and 9 years following Tdap vaccination, in terms of the percentage of participants with antibody concentrations above the assay cut-offs.",
            "startOffset": 26796,
            "title": "Study objectives"
        },
        {
            "endOffset": 21326,
            "parents": [],
            "refoffsets": {
                "b0010": {
                    "endOffset": 21215,
                    "startOffset": 21212
                },
                "b0015": {
                    "endOffset": 21325,
                    "startOffset": 21322
                }
            },
            "secId": "s0005",
            "sentence": "Despite good control of the disease in young children, with high worldwide vaccination coverages reported for 1 (91%) and 3 (86%) doses of diphtheria-tetanus-pertussis (DTP) vaccines in 2016 [2], the overall number of reported pertussis cases has risen cyclically with peaks occurring every 3\u20135 years [3].",
            "startOffset": 21021,
            "title": "Introduction"
        },
        {
            "endOffset": 24056,
            "parents": [],
            "refoffsets": {
                "b0090": {
                    "endOffset": 24055,
                    "startOffset": 24051
                }
            },
            "secId": "s0005",
            "sentence": "In a previous study, we showed that the immunogenicity and safety of a reduced-antigen content Tdap vaccine (Tdap-B; Boostrix US formulation, GSK) were comparable to that elicited by the standard-of-care at that moment (Tdap-A; Adacel, Sanofi-Pasteur) in adults 19\u201364 years of age [18].",
            "startOffset": 23770,
            "title": "Introduction"
        },
        {
            "endOffset": 34927,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Therefore, non-inferiority of immune response of a second dose of Tdap vaccine (Tdap-B and Tdap-A groups) to a 3-dose series of DTPa was demonstrated for all 3 pertussis antigens in terms of antibody GMCs.",
            "startOffset": 34722,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 37201,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The complementary sensitivity analysis performed on the ATP cohort for immunogenicity at Year 9 demonstrated that the drop-out rates had no impact on the immunogenicity results (Table S4).",
            "startOffset": 37013,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 39383,
            "parents": [],
            "secId": "s0065",
            "sentence": "The percentage of participants with seroprotective levels decreased only slightly up to Year 9 compared to levels one month post-vaccination and both the seroprotection rates and antibody GMCs were higher at Years 5 and 9 than pre-vaccination levels for the 2 antigens.",
            "startOffset": 39114,
            "title": "Discussion"
        },
        {
            "endOffset": 38119,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "Fatigue and headache were the most frequently reported solicited general AEs, being documented for 71 (23.2%) and 52 (17.0%) participants in the Tdap-B group, 23 (16.8%) and 25 (18.2%) participants in the Tdap-A group and 51 (14.2%) and 53 (14.8%) participants in the Control group.",
            "startOffset": 37837,
            "title": "Safety"
        },
        {
            "endOffset": 21020,
            "parents": [],
            "refoffsets": {
                "b0005": {
                    "endOffset": 21019,
                    "startOffset": 21016
                }
            },
            "secId": "s0005",
            "sentence": "Pertussis is a highly-contagious infectious respiratory disease which, although being vaccine-preventable, remains to date a global public health concern [1].",
            "startOffset": 20862,
            "title": "Introduction"
        },
        {
            "endOffset": 43316,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 43315,
                    "startOffset": 43311
                }
            },
            "secId": "s0065",
            "sentence": "Seropositivity rates of 48.3% for PT, 97.4% for FHA and 89.0% for PRN were previously reported in individuals aged 18\u2013<64 years at 10 years post-vaccination with a Tdap-A booster dose, although the decline for PT was less steep in adolescents, with 64.3% maintaining seropositive levels [17].",
            "startOffset": 43024,
            "title": "Discussion"
        },
        {
            "endOffset": 25931,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The complete list of inclusion and exclusion criteria is presented in the Supplementary Material, Text S1.",
            "startOffset": 25825,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37013,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "GMC ratios between groups for all antigens one month after booster vaccination were between 0.66 and 1.21 for Tdap-B group over Control group and 0.68 and 1.52 for Tdap-A group over Control group (Table S3).",
            "startOffset": 36806,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 32935,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "Reasons for exclusion from the ATP cohorts are presented in Fig. 1.",
            "startOffset": 32868,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 35687,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The non-inferiority margins for the difference between groups in the booster response rate (Tdap-B or Tdap-A minus Control group) were met only for PT in the Tdap-B group and FHA in the Tdap-A group (Table 2).",
            "startOffset": 35478,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 36319,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Therefore, non-inferiority of 2 Tdap doses versus 1 dose was not demonstrated regarding booster response to all vaccine antigens.",
            "startOffset": 36190,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 33011,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0045",
            "sentence": "The demographic characteristics at each timepoint are presented in Table S1.",
            "startOffset": 32935,
            "title": "Demographic characteristics"
        },
        {
            "endOffset": 28703,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "The fourth co-primary objective assessed non-inferiority of the immune response elicited by the second Tdap dose to that elicited by a first Tdap-B dose in terms of booster response against vaccine antigens, using the same statistical criterion as the second co-primary objective.",
            "startOffset": 28423,
            "title": "Study objectives"
        },
        {
            "endOffset": 26394,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.",
            "startOffset": 26285,
            "title": "Study design and participants"
        },
        {
            "endOffset": 37389,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "The complementary sensitivity analysis performed on the ATP cohort for immunogenicity at Year 9 demonstrated that the drop-out rates had no impact on the immunogenicity results (Table S4).",
            "startOffset": 37201,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 45780,
            "parents": [],
            "secId": "s0065",
            "sentence": "However, the changes in assays and cut-offs hindered comparisons between immunogenicity results at different timepoints and to older studies.",
            "startOffset": 45639,
            "title": "Discussion"
        },
        {
            "endOffset": 46246,
            "parents": [],
            "secId": "s0065",
            "sentence": "A lay language graphical summary contextualizing the results of the study and potential impact is displayed in the Focus on Patient Section (Fig. 3).",
            "startOffset": 46097,
            "title": "Discussion"
        },
        {
            "endOffset": 46599,
            "parents": [],
            "secId": "s0075",
            "sentence": "Boostrix and Infanrix are trademarks of the GSK group of companies.",
            "startOffset": 46532,
            "title": "Trademark statement"
        },
        {
            "endOffset": 26065,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Supplementary data associated with this article can be found, in the online version, at https://doi.org/10.1016/j.vaccine.2018.08.051.",
            "startOffset": 25931,
            "title": "Study design and participants"
        },
        {
            "endOffset": 38637,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "At least one grade 3 unsolicited AE was reported for 5 (1.6%) participants in the Tdap-B group, 3 (2.2%) participants in the Tdap-A group and 9 (2.5%) participants in Control group.",
            "startOffset": 38456,
            "title": "Safety"
        },
        {
            "endOffset": 34279,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At each timepoint, GMCs were in the same ranges in the 2 groups or higher values were observed in group Tdap-B compared to group Tdap-A (Table 1).",
            "startOffset": 34133,
            "title": "Persistence of immune response"
        },
        {
            "endOffset": 22077,
            "parents": [],
            "refoffsets": {
                "b0045": {
                    "endOffset": 22076,
                    "startOffset": 22073
                }
            },
            "secId": "s0005",
            "sentence": "In the US, current guidelines recommend that individuals 11\u201318 years of age receive a single dose of Tdap [9].",
            "startOffset": 21967,
            "title": "Introduction"
        },
        {
            "endOffset": 25824,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Healthy adults who received vaccination in the initial study were eligible to participate in the extension study.",
            "startOffset": 25711,
            "title": "Study design and participants"
        },
        {
            "endOffset": 45638,
            "parents": [],
            "secId": "s0065",
            "sentence": "Our study provided information on the immunogenicity, reactogenicity and safety data on a second dose of Tdap vaccine, and antibody persistence of antibodies over 9 years post-initial vaccination, in a population which is the most affected by waning immunity to pertussis.",
            "startOffset": 45366,
            "title": "Discussion"
        },
        {
            "endOffset": 46732,
            "parents": [],
            "secId": "s0080",
            "sentence": "This study and related publication were sponsored by GlaxoSmithKline Biologicals S.A.",
            "startOffset": 46647,
            "title": "Funding"
        },
        {
            "endOffset": 28948,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Secondary objectives included assessing antibody levels and alternate booster responses for all Tdap antigens at all timepoints and comparing the safety and reactogenicity of a second dose of Tdap to that of first dose of Tdap vaccine at Year 9.",
            "startOffset": 28703,
            "title": "Study objectives"
        },
        {
            "endOffset": 46640,
            "parents": [],
            "secId": "s0075",
            "sentence": "Adacel is a trademark of Sanofi-Pasteur.",
            "startOffset": 46600,
            "title": "Trademark statement"
        },
        {
            "endOffset": 35817,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Therefore, non-inferiority of 2 Tdap doses versus 1 dose was not demonstrated regarding booster response to all vaccine antigens.",
            "startOffset": 35688,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 26777,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study is registered at www.clinicaltrials.gov (NCT00489970); a protocol summary is available at https://www.gsk-clinicalstudyregister.com/study/110080#ps.",
            "startOffset": 26619,
            "title": "Study design and participants"
        },
        {
            "endOffset": 23662,
            "parents": [],
            "refoffsets": {
                "b0085": {
                    "endOffset": 23661,
                    "startOffset": 23657
                }
            },
            "secId": "s0005",
            "sentence": "In another study in adults, antibody levels decreased to pre-vaccination levels within one year after the administration of a Tdap booster dose for PT and declined substantially within 5 years post-vaccination for filamentous hemagglutinin (FHA) and pertactin (PRN) [17].",
            "startOffset": 23391,
            "title": "Introduction"
        },
        {
            "endOffset": 23770,
            "parents": [],
            "secId": "s0005",
            "sentence": "Therefore, boosting might be needed at regular intervals to afford continuous protection against pertussis.",
            "startOffset": 23663,
            "title": "Introduction"
        },
        {
            "endOffset": 25337,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "Additionally, healthy adults 28\u201373 years of age were enrolled at the Year 9 timepoint to act as control (Control group) (Fig. 1); enrollment was also stratified by age.",
            "startOffset": 25169,
            "title": "Study design and participants"
        },
        {
            "endOffset": 29405,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0105": {
                    "endOffset": 29404,
                    "startOffset": 29400
                }
            },
            "secId": "s0025",
            "sentence": "During the study, the assays and cut-offs were revalidated [21].",
            "startOffset": 29341,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 31032,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "The power to demonstrate non-inferiority to the Control group in terms of booster response for all 5 antigens simultaneously was 48.7% in the Tdap-B and 4.1% in the Tdap-A group.",
            "startOffset": 30854,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41854,
            "parents": [],
            "refoffsets": {
                "b0145": {
                    "endOffset": 41853,
                    "startOffset": 41849
                }
            },
            "secId": "s0065",
            "sentence": "Our data are in line with observations in young Belgian adults aged 20\u201328 years, with all participants maintaining antibody concentrations \u22650.1 IU/mL for both diphtheria and tetanus 10 years after receiving Tdap-B containing different doses of aluminium [29].",
            "startOffset": 41595,
            "title": "Discussion"
        },
        {
            "endOffset": 26618,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The study protocol and informed consent were reviewed and approved by an Institutional Review Board at each center.",
            "startOffset": 26503,
            "title": "Study design and participants"
        },
        {
            "endOffset": 24307,
            "parents": [],
            "secId": "s0005",
            "sentence": "However, information regarding the long-term persistence of antibodies following vaccination with Tdap-B is still needed.",
            "startOffset": 24186,
            "title": "Introduction"
        },
        {
            "endOffset": 33356,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At Year 9, \u226598.3% and \u226598.1% of participants in the 2 groups had seroprotective levels against diphtheria and tetanus, respectively.",
            "startOffset": 33224,
            "title": "Persistence of immune response"
        },
        {
            "endOffset": 27820,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Non-inferiority was confirmed if one month post-vaccination the lower limit (LL) of the 97.5% confidence interval (CI) for the between-groups difference in the seroprotection rate (Tdap-B or Tdap-A group minus Control group) against diphtheria and tetanus antigens was \u2265\u221210%.",
            "startOffset": 27545,
            "title": "Study objectives"
        },
        {
            "endOffset": 32555,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Antibody GMCs were computed by taking the anti-log of the mean of the log concentration transformations, with concentrations below the assay\u2019s cut-off being given an arbitrary value of half the cut-off.",
            "startOffset": 32353,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 41337,
            "parents": [],
            "secId": "s0065",
            "sentence": "Moreover, non-inferiority was demonstrated in terms of seroprotection rates/antibody GMCs and robust increases in antibody GMCs were observed one month post-vaccination compared to pre-booster levels.",
            "startOffset": 41137,
            "title": "Discussion"
        },
        {
            "endOffset": 37669,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0060",
            "sentence": "The most common solicited local AE was pain, reported for 180 (58.8%), 84 (61.3%) and 132 (36.9%) participants in the Tdap-B group, Tdap-A group and Control group, respectively.",
            "startOffset": 37492,
            "title": "Safety"
        },
        {
            "endOffset": 35130,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "One month post-vaccination with Tdap-B, the percentages of participants with antibody concentrations \u22650.1 IU/mL for diphtheria and tetanus were \u226599.2% in both Tdap groups and \u226597.9% in the Control group.",
            "startOffset": 34927,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 40839,
            "parents": [],
            "secId": "s0065",
            "sentence": "Non-inferiority of 2 Tdap doses versus 1 Tdap dose was not demonstrated with respect to booster response rates one month post-administration of Tdap-B at Year 9.",
            "startOffset": 40678,
            "title": "Discussion"
        },
        {
            "endOffset": 23390,
            "parents": [],
            "refoffsets": {
                "b0080": {
                    "endOffset": 23389,
                    "startOffset": 23385
                }
            },
            "secId": "s0005",
            "sentence": "In adults 25\u201329 years of age receiving a first booster dose of Tdap, a rapid decline of anti-pertussis toxoid (PT) levels was observed in the first year, followed by a more limited decay in the second year post-booster vaccination; a median level of PT-IgG \u2265 international units (IU)/mL, assumed to indicate protection against B. pertussis, was predicted to be maintained for 9 years following the booster dose [16].",
            "startOffset": 22974,
            "title": "Introduction"
        },
        {
            "endOffset": 31398,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Immunogenicity of the Tdap-B dose was assessed in the ATP cohort for immunogenicity at Year 9, which included all evaluable participants who received a dose of vaccine and had available immunogenicity data.",
            "startOffset": 31192,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 25048,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0090": {
                    "endOffset": 25047,
                    "startOffset": 25043
                }
            },
            "secId": "s0015",
            "sentence": "In the initial study (NCT00346073), participants were randomized 2:1 in one of 2 groups to receive either Tdap-B (Tdap-B group) or Tdap-A (Tdap-A group) and stratified by age (19\u201329 years, 30\u201349 years and 50\u201364 years) [18].",
            "startOffset": 24825,
            "title": "Study design and participants"
        },
        {
            "endOffset": 35979,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "Booster response rates in the Tdap groups were \u226560.2% for diphtheria, \u226536.7% for tetanus and ranged from 77.5% to 96.7% for pertussis antigens (Table 2, Fig. S1).",
            "startOffset": 35817,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 36805,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "In exploratory analyses, similar percentages of participants with alternate booster response were observed in the 2 Tdap groups (Table S2).",
            "startOffset": 36666,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 26285,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "The complete list of inclusion and exclusion criteria is presented in the Supplementary Material, Text S1.",
            "startOffset": 26179,
            "title": "Study design and participants"
        },
        {
            "endOffset": 44392,
            "parents": [],
            "refoffsets": {
                "b0130": {
                    "endOffset": 44391,
                    "startOffset": 44387
                }
            },
            "secId": "s0065",
            "sentence": "Although different definitions of the booster response were used in clinical trials, results in the Tdap-B group compare well with those from a decennial study conducted in Australia, in which a second dose of Tdap elicited a higher booster response rate for PT (97.4%) and FHA (78.3%) than for PRN (69.7%) [26].",
            "startOffset": 44080,
            "title": "Discussion"
        },
        {
            "endOffset": 30160,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Adverse events (AEs) following vaccination at Year 9 were recorded by participants on diary cards.",
            "startOffset": 30062,
            "title": "Safety assessment"
        },
        {
            "endOffset": 25168,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "In the extension study, antibody persistence was evaluated in both groups at 1, 3, 5 and 9 years following vaccination.",
            "startOffset": 25049,
            "title": "Study design and participants"
        },
        {
            "endOffset": 30042,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0025",
            "sentence": "Booster and alternate booster responses were evaluated at Year 9, one month post-vaccination with Tdap-B.",
            "startOffset": 29937,
            "title": "Immunogenicity assessment"
        },
        {
            "endOffset": 30323,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0030",
            "sentence": "Solicited local and general AEs were reported within 4 days post-vaccination, while unsolicited and serious AEs (SAEs) were recorded for 31 days post-vaccination.",
            "startOffset": 30161,
            "title": "Safety assessment"
        },
        {
            "endOffset": 41411,
            "parents": [],
            "secId": "s0065",
            "sentence": "Taken together, these results support the immunogenicity of 2 Tdap doses.",
            "startOffset": 41338,
            "title": "Discussion"
        },
        {
            "endOffset": 24825,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0015",
            "sentence": "This phase III, controlled, open-label, multicenter, extension study was conducted between June 2007 and March 2016 in the US.",
            "startOffset": 24699,
            "title": "Study design and participants"
        },
        {
            "endOffset": 28242,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "refoffsets": {
                "b0100": {
                    "endOffset": 28241,
                    "startOffset": 28237
                }
            },
            "secId": "s0020",
            "sentence": "The third co-primary objective evaluated the non-inferiority of the immune response to pertussis components elicited by a second dose of Tdap vaccine (administered 9 years after a first Tdap dose) to the immune response induced by a 3-dose series of a combined diphtheria-tetanus-acellular pertussis vaccine (DTPa, Infanrix, GSK) administered during infancy in a household contact efficacy study conducted in Germany [20].",
            "startOffset": 27820,
            "title": "Study objectives"
        },
        {
            "endOffset": 32353,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Additionally, a sensitivity analysis was performed to evaluate the robustness of GMC results with respect to drop-out from the initial study and exploratory between-group comparisons were conducted (see Text S2).",
            "startOffset": 32141,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 24442,
            "parents": [],
            "secId": "s0005",
            "sentence": "Moreover, in the US, no data is available on the immunogenicity and safety of Tdap-B given as a second decennial dose of Tdap vaccine.",
            "startOffset": 24308,
            "title": "Introduction"
        },
        {
            "endOffset": 32604,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0035",
            "sentence": "Statistical analyses were performed using SAS v9.",
            "startOffset": 32555,
            "title": "Statistical analyses"
        },
        {
            "endOffset": 33800,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0050",
            "sentence": "At Year 5, the percentage of participants with antibody concentrations above the assay cut-off (\u226576.6% for PT; \u226599.2% for FHA and \u226596.5% for PRN) was comparable between the Tdap-B and Tdap-A groups for FHA and PRN, while a higher value for PT was observed in group Tdap-B compared to group Tdap-A, based on non-overlapping 95% CIs.",
            "startOffset": 33469,
            "title": "Persistence of immune response"
        },
        {
            "endOffset": 34637,
            "parents": [
                {
                    "id": "s0040",
                    "title": "Results"
                }
            ],
            "secId": "s0055",
            "sentence": "One month following Tdap-B administration, the pre-defined criteria for the first co-primary objective were met (Table 2); thus, non-inferiority of the immune response to diphtheria and tetanus antigens in both Tdap groups when compared to the Control group was demonstrated in terms of seroprotection rates.",
            "startOffset": 34329,
            "title": "Immune response following vaccination at Year 9"
        },
        {
            "endOffset": 27167,
            "parents": [
                {
                    "id": "s0010",
                    "title": "Methods"
                }
            ],
            "secId": "s0020",
            "sentence": "Similarly, a secondary objective assessed persistence of antibodies against pertussis antigens in the same terms.",
            "startOffset": 27054,
            "title": "Study objectives"
        },
        {
            "endOffset": 41594,
            "parents": [],
            "secId": "s0065",
            "sentence": "In our study, seroprotective levels for diphtheria and tetanus were still observed for \u226598% of participants up to 9 years post-vaccination with either a Tdap-B or Tdap-A booster dose.",
            "startOffset": 41411,
            "title": "Discussion"
        }
    ],
    "docId": "S0264410X18311800",
    "metadata": {
        "asjc": [
            "1313",
            "2400",
            "2725",
            "2739",
            "3400"
        ],
        "authors": [
            {
                "email": "dbrandon@crftrials.com",
                "first": "Donald",
                "initial": "D.",
                "last": "Brandon"
            },
            {
                "email": "mkimmel@optimalsites.net",
                "first": "Murray",
                "initial": "M.",
                "last": "Kimmel"
            },
            {
                "email": "sherine.o.kuriyakose@gsk.com",
                "first": "Sherine O.",
                "initial": "S.O.",
                "last": "Kuriyakose"
            },
            {
                "email": "lusine.x.kostanyan@gsk.com",
                "first": "Lusin\u00e9",
                "initial": "L.",
                "last": "Kostanyan"
            },
            {
                "email": "narcisa.x.mesaros@gsk.com",
                "first": "Narcisa",
                "initial": "N.",
                "last": "Mesaros"
            }
        ],
        "doi": "10.1016/j.vaccine.2018.08.051",
        "firstpage": "6325",
        "issn": "0264410X",
        "keywords": [
            "Adults",
            "Booster immunization",
            "Persistence",
            "Reduced-antigen-content diphtheria\u2013tetanus\u2013acellular pertussis vaccine"
        ],
        "lastpage": "6333",
        "openaccess": "Full",
        "pub_year": 2018,
        "subjareas": [
            "BIOC",
            "IMMU",
            "MEDI",
            "VETE"
        ],
        "title": "Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults"
    }
}